Effects of Phenobarbital, a Drug Used to Treat Epilepsy, on Intestinal Flora, Bifidobacterium Sp. by Tucker, Kayleen R.
THE EFFECTS OF PHENOBARBITAL, A DRUG USED
TO TREAT EPILEPSY, ON INTESTINAL FLORA,
BIFIDOBACTERIUM SP.
By
KAYLEEN R. TUCKER
Bachelor ofScience
University ofNebraska
Lincoln~ Nebraska
1998
Submitted to the Faculty of the
Graduate College of the
Oklahoma State University
in partial fulfillment of
the requirements for
the degree of
MASTERS OF SCIENCE
December 2000
THE EFFECTS OF PHENOBARBITAL. A DRUG USED
TO TREAT EPILEPSY. ON INTESTINAL FLORA,
BIFIDOBACTERIUM SP.
Thesis Approved:
------"$~D.JI.eTtheGr~'-·_---
11
ACKNOWLEDGEMENTS
I would like to acknowledge the multitude of people that have contributed to the contents
of this thesis, physically and emotionally. There are many graduate students of the
Entomology and Microbiology and Molecular Genetics departments who have helped
throughout the writing of this thesis that I would like to acknowledge. Behind every
student, is a driving force that keeps him or her motivated to study or on task to finish the
writing of a thesis. For this, I would like to thank my parents, James and Connie Tucker
who have always supported me in accomplishing the goals I have set for myself. I
dedicate this thesis and degree to my parents. Last, but definitely not least, I would like
to thank my fiance, Charles Joyce for his love and support throughout this graduate
school adventure ride.
iii
Chapter
TABLE OF CONTENTS
Page
I. INTRODUCTION AND REVIEW OF LITERATURE 1
Scope and Purpose 1
Introduction to First Study 3
Introduction to Second Study 6
II. IDENTIFICATION OF PHENOBARBITAL-INDUCED 9
PROTEINS FROM BIFIDOBACTERJUM SP.
Introduction 9
Materials and Methods 9
Results 15
Discussion 17
III. THE METABOLISM OF PHENOBARBITAL, A DRUG 22
USED FOR EPILEPSY, BY INTESTINAL FLORA,
BIFIDOBACTERIUMADOLESCENT/S AND B. BIF/DUM.
Introduction 22
Materials and Methods 24
Results 25
Discussion 27
IV. CONCLUSIONS AND DISCUSSION 47
REFERENCES 50
VITA 5j
IV
LIST OF TABLES
Table Page
1. Typical Representation ofthe gastrointestinal microflora 8
2. Doubling Time for B. adolescentis and B. bifidum 30
3. Percentage ofproduct generated for B. adolescentis and B. bifidum 31
v
LIST OF FIGURES
Figures Page
1. SDS-PAGE gel ofB. adolescentis 18
2. SDS-PAGE gel ofB. bifidum 19
3. SDS-PAGE gel ofB. breve and B. infantis 20
4. SDS-PAGE gel of B. breve and B. longum 21
5. Growth Curve of B. adolescentis 32
6. Growth Curve of B. bifidum 33
7. Slope of the Log Phase vs. Various Concentrations ofPhenobarbital .34
8. GCIMS Results for B. adolescentis 0 roM Phenobarbital.. .35
9. GCIMS Results for B. adolescentis 5 mM Degradation Control.. 36
to. GelMS Results for B. adolescentis 5 mM PhenobarbitaL 37
11. GCIMS Results for B. adolescentis 10 mM Phenobarbital 38
12. GCIMS Results for B. adolescentis 20 mM Phenobarbital .39
13. GCIMS Results for B. bifidum 0 mM Phenobarbital.. .40
14. GCIMS Results for B. bifidum 5 roM Phenobarbital... .41
15. GC/MS Results for B. bifidum 10 mM Phenobarbital .42
16. GC/MS Results for B. bifidum 20 mM Phenobarbital.. .43
17. Ratio of Benzeneacetamide/ Phenobarbital vs. Concentration .44
18. Metabolism of Phenobarbital .45
vi
19. Structure of Phenobarbital 46
vii
CHAPTER 1
INTRODUCTION AND REVIEW OF LITERATURE
Overview of Study
Scope and purpose. Collectively, microbes exhibit unparalleled metabolic diversity and
adaptability, allowing them to survive in environments incompatible with large life
fonns. Microbes produce energy and carry out metabolism from a tremendous variety of
organic materials and, in addition, can use radiant energy. Microbes can survive in the
hot springs of Yellowstone Park and in Antarctica, in soil and in water, in the bottom of
lakes and in compost heaps. and within and on the surfaces of both animals and plants.
The ability of microbes to adapt and survive in a diversity of environments exceeds, by
orders of magnitude, the survival ability of large life fonns. Although, from the
morphological viewpoint, microbes are simple, they are metabolically and
physiologically complex. In contrast, collectively, large fonns, although structurally
complex, are, relatively speaking, physiologically simple. It is precisely because of the
physiological and metabolic complexity of microbes that they can survive in such a wider
variety of circumstances than can elephants and other large fonns (6).
The metabolic capacity of the gut bacteria is extremely diverse (14, 36). Studies
on the metabolic fate of drugs and foreign organic compounds up to the present have
dealt almost exclusively with the changes occurring in the tissues. These reactions
include oxidation, reduction, hydrolysis and conjugation and have been the subject of a
review by GILLETTE (1963) (13,34).
As complex as the twists and turns of the intestinal tract, so is the diversity of the
microorganisms that inhabit it. (See Table 1) In man, the small intestine is sparsely
populated with microorganisms, most of which are aerobic or facultatively anaerobic in
nature. Below the ileocecal valve, the proportion of anaerobic microorganisms increases
to the point where they outnumber aerobes and facultative anaerobes by a factor of 103 to
104 (9,36).
Any compound taken orally, any substance entering the intestine via the biliary
tract or the bloodstream, or any substance secreted directly into the lumen is a potential
substrate for bacterial transformation (14). Xenobiotics are foreign chemicals that are
man made or of natural origin, such as drugs, pesticides, or environmental pollutants
(21). The human body has a number of biochemical processes, located in the kidney,
liver and gut that convert lipophilic compounds to more hydrophilic metabolites, and
eliminate them from the body via urine, feces, or expired air. The key to understanding
the role of intestinal microflora is to characterize the protein inductions by a xenobiotic,
and their possible role in metabolism (7).
Introduction to the Two Studies
Screening of Intestinal Flora, Bifidobacterium sp., for the Presence of a Drug
Metabolizing Enzyme Complex
Drug metabolizing enzymes are responsible for the increased or decreased
toxicity of foreign compounds, or xenobiotics. Xenobiotics are compounds that are not
used as energy substrates or as building blocks for biological matrices(36). One enzyme
that has been extensively studied in this manner is the Cytochrome P450 system. The
cytochrome P450 enzyme family is responsible for the metabolism of a large number of
drugs and environmental pollutants in mammals (35). Cytochrome P450, initially
identified as a pigment from liver with a characteristic absorption peak at 450 nm when
bound in the reduced state to carbon monoxide, is actually a multigene family of heme
proteins that are found in essentially all eukaryotes and in some bacteria (12).
The cytochromes P-450 (P-450s) constitute an extremely large family
('superfamily') of haemoproteins that catalyze the oxidation of a wide range of
physiological and non-physiological compounds(31, 41). All have characteristic ferrous
carbon monoxide complex peaks near 450 nm, have monomeric molecular weights of
about 50,000, and accept electrons from the flavoprotein NADPH-P-450 reductase(10,
18). A remarkable feature of the P-4S0's is the manipulation of the same basic structure
and chemistry to achieve an enormous range of functions in organisms as diverse as
bacteria and man. Indeed, the P-450s have been described as 'the most versatile
biological catalyst known' (30). This is due to cytochrome P450s ability to bind with a
variety of substrates and the conversion to new compounds. In addition to metabolizing
several foreign compounds, the cytochrome P4S0 superfamily has a role in the
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deactivation and activation of chemical carCinogens. The majority of toxic and
carcinogenic chemicals do not produce their detrimental effects by themselves, except
perhaps in small doses. In most cases, activation to electrophilic fonus is necessary to
produce molecules capable of reacting irreversibly with tissue nucleophiles (19).
Considerable evidence has now been accumulated in support of the view that changes in
P-450 composition can affect in vitro and in vivo metabolism of drugs in both animal
models and humans(24, 32). The evidence is less clear in the case of carcinogens, which
cannot be dealt with so easily in humans (18). During the past several years, it has
become widely recognized that marked species differences occur among the foreign
compound-metabolizing P-450s (15). Mammals are unique in that they possess their own
eukaryotic P-450 system while some of the microorganisms that live symbiotically in
animal gut, can possess their own bacterial P450 enzyme system(8).
Even though the microsomal cytochrome P-4S0 is classed as an oxygenase(11), it
also catalyzes the reductive biotransformation of certain xenobiotics. These reactions
proceed most readily under conditions of low oxygen tension. Owing to the transfer to
reducing equivalents in cytochrome P-450-catalyzed reactions, certain xenobiotic
substrates may accept one or two of these electrons. In effect, the substrate rather than
molecular oxygen accepts the electrons and is reduced(23).
Intestinal microflora are also known to mediate the reduction of a number of
chemicals, particularly those with a1.o or nitro groups(36). These microbes have virtually
all the enzymatic machinery to mimic the cytochrome P-4S0-mediated reactions observed
in mammalian systems(42). Owing to the anaerobic environment and the high
concentration of chemical seen upon ingestion or biliary excretion, these microbes can
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have a substantial effect on the in vivo biotransformation of xenobiotics. These microbes
may also further modify metabolites of xenobiotics that were produced by hepatic
cytochrome P-4S0. In some instances, a new reductive metabolite may be reabsorbed
and further processed by hepatic enzymes (23).
A number of microorganisms possess monooxygenases similar to those found in
mammalian tissues. Interestingly, the closest correlation exists between eukaryotic
organisms and mammals (both possessing monooxygenases) in contrast to prokaryotic
microorganisms which seem to produce a preponderance ofdioxygenase enzymes (36).
After passage through the liver, drugs and other foreign compounds (or their
metabolites) can pass into the systemic circulation where they may ultimately be
eliminated by the kidneys. Alternatively, compounds may be excreted into the intestine
via the bile. In some instances, reabsorption and enterohepatic circulation between the
liver and intestine may occur (36). For the purpose of this paper, biliary secretion can be
thl1ught of as a mechanism whereby xenobiotics and their metabolites corne in contact
with intestinal microflora.
The Metabolism of Phenobarbital, a Drug Used for Epilepsy, by Intestinal Flora,
Bifidobacterium adolescentis and Bifulobacterium bifidum.
Phenobarbital is an antiepileptic drug used to treat tonic clonic and partial
seIzures. As an effective stimulator of P450 enzymes, its use leads to increased
metabolism of several drugs, including other antiepileptics, carbamazepine, and valproic
acid(3 7, 38). The long elimination half-life of phenobarbital means that the drug must be
administered in a loading dose to rapidly achieve a therapeutic blood concentration(40).
The drug is addictive, and evidence of a withdrawal "syndrome" may present if the drug
is discontinued suddenly. The most troublesome adverse effects of phenobarbital are
sedation and negative effects on cognition, particularly in children (40).
The primary site of action for phenobarbital appears to be the motor cortex where
the spread of seizure activity is inhibited. Possibly by promoting sodium efflux from
neurons, it tends to stabilize the threshold, caused by K+, against hyperexcitability caused
by excessive stimulation or environmental changes capable of reducing membrane
sodium gradient. Phenobarbital reduces the maximal activity of the brain stem centers
responsible for the tonic phase of tonic-clonic (grand mal) seizures(2).
The primary pathway for the metabolism of phenobarbital is hydroxylation of the
phenyl ring. Butler (5) isolated p-hydroxy-phenobarbital in pure form from the urine of
man and canine and proved its structure by synthesis. The extent to which phenobarbital
is converted to this compound and its conjugates are not known. However, Butler noted
that in urine specimens the concentration of the metabolite was more than five times
higher than that of the drug. Based on this evidence, it is believed that the para-hydroxy
derivative is the major metabolite of phenobarbital (43). Other research indicates that
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phenobarbital contains two pnmary metabolites, parahydroxyphenobarbital and
phenobarbital N-glucoside (I).
The significance of this study is that Bifidobacterium is a major intestinal strain
commonly found in many individuals and its ability to metabolize xenobiotics, such as
phenobarbital, may have a profound effect on the physiology of the host. Secondly, as
probiotic therapy is becoming more popular, it is important that we understand the
different metabolic systems that are found in wild strains (ATCC Bifidobacterium) and
probiotic strains (Bifidobacterium sp.). Lastly, characterizing Bifidobacterium's
metabolic capacity in terms of whether enzyme systems, such as cytochrome P450, exist
is important as they may participate in the metabolism and generation of detoxified or
toxified products, which can have a positive or negative effect on human health.
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Table 1: Representation of the gastrointestinal microflora (33).
Microorganisms Description
.-
1. Bacteroides Gram-negative, strictly anaerobic, non-
spore fonning rods
2. Lactobacilli Gram-positive rods
1. Anaerobic (BiJidobacterium)
2. Aerobic
Fusobacterium Gram-negative, strictly anaerobic,
spindle shaped rods
Enterobacteria Gram-negative, aerobic or facultatively
1. Escherichia coli anaerobic, non-spore forming rods
2. Aerobacter
3. Klebsiella
4. Proteus
5. Providence group
1. Clostridia Gram-positive, anaerobic,
spore-forming rods
2. Streptococci Gram-positive, aerobic or facultatively
1. Enterococci anaerobic cocci
2. Anaerobic Gram-positive, anaerobic cocci
3. Pseudomonads Gram-negative, aerobic, motile rods
1. Pseudomonas
2. Alcalif(enesfaecalis
4. Staphylococci Gram-positive, aerobic or facultatively
anaerobic cocci
5. Vcillonella Gram-negative, anaerobic cocci
6. Yeast
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CHAPTER 2
IDENTIFICATION OF PHENOBARBITAL-INDUCED PROTEINS FROM
BIFIDOBACTERJUM SPP.
Introduction. The objective of this study is to determine if phenobarbital, an inducer of
cytochrome P450, causes an induction of proteins. The strains were selected based on the
results of quantitative and qualitative examination of the normal flora of 20 Japanese-
Hawaiians(39). Eighteen of the most common strains studied by Moore were selected for
our study. Five strains of Bifidobacterium sp. were tested. The chosen species were B.
adolescentis, B. bifidum, B. breve, B. infantis, and B. lvngum. The following techniques
were used to determine whether a protein induction, possibly cytochrome P450, was
present. The techniques were anaerobic culture and growth, chemical induction, semi-
pure protein extraction and determination, SDS-PAGE, silver stain, isoelectric focusing,
and CO difference spectrum analysis.
Materials and Methods.
Inoculation and Growth of Anaerobic bacterial strains.
Five Bifidobacterium spp. were tested: B. adolescentis, B. bifidum, B. breve, B. infantis,
and B. longum. A I ml amount of confluent Bifidobacterium sp. from chopped meat
media was collected in a syringe and injected into a 15 ml test tube containing 7 ml of
manufactured Anaerobe Systems Chopped Meat Carbohydrate with airtight Hungate
Caps. The samples were incubated at 37°C for 48 hours, or until growth was evident by
clouding of the test tube. Optical density was not taken. A 5 ml culture was then injected
into an 18 ml KIMAX airtight test tube containing 5 ml of TYG media. This tube was
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incubated at 37° Celsius for 48 hours. The TYG media was prepared using 5 g of
tryptone, 2.5 g of yeast extract into 425 ml deionized water. 12.5 ml of salt solution 1,
12.5 ml of salt solution 2, 12.5 ml of CaCh, 2 ml of hemin, 1 ml of microminerals, and 5
ml of resazurin. The 500 ml solution was heated until boiling for 5 minutes in the
microwave on a high setting, and degassed under N2 for a minimum of 30 minutes. The
TYG was cooled to approximately 40°C, and 5ml of Vitamin K solution and 0.3g of
Cysteine-HCI was mixed and added via syringe. The solution was adjusted to the pH of
7.0, and bubbled with N2 for an additional 10 minutes. Simultaneously, to a 100ml bottle
the following were added: 10ml Water, lOml Volatile Fatty Acid Solution, and 0.2g
Sodium Carbonate. The bottle was stoppered, sealed and autoclaved with the TYG
media. Following sterilization, the TYG media was bubbled under N2 until cooled to less
than 50°e. To the TYG, 20ml of 20% Glucose, 10ml of Reducing Agent (optional), and
1ml of lOx Vitamins was aseptically added. The sterile TYG media was placed into the
N2 37°C incubator overnight. A 5ml amount of each Bifidobacterium sp. was added to
each 500ml bottle of sterile TYG media. To verify purity, a gram stain and visual check
for consistency was performed on the Bifidobacterium inoculum prior to inoculation of
the TYG media.
Induction of Bifidobacterium spp. with Phenobarbital.
A 0.58g amount of Phenobarbital (5-Ethyl-5-phenyl-2,4,6-trioxohexahydropyrimidine)
was dissolved in 10ml of anaerobic ddH20. Using a 0.20 J..lM filter and syringe, 1 ml of
the phenobarbital solution was injected into the 500 ml TYG container making a final 5
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mM phenobarbital concentration. All additions were performed inside the anaerobic
nitrogen chamber. The sample was incubated for 24-48 hours. To ensure purity, a gram
stain was performed, following incubation.
Acquisition of Supernatants I and II.
Because Bifidobacterium spp. are anaerobic bacteria, all procedures were perfonned
anaerobically. All dishware (bottles, pipettes, pipette tips, etc) were placed into the
anaerobic nitrogen chamber at least 24 hours prior to use, which allowed them to
adapt/adjust to the anaerobic conditions. A I L amount of MOPS Anaerobic Buffer was
prepared using 100 mM MOPS, 10% glycerol, I mM EDTA. The solution was adjusted
to a pH of 7.3 and heated to boiling in the microwave for 6 min/500 m!. The solution
was degassed under N2 for 60 min. Following sterilization, the solution was degassed
under N2 for 5 h. Prior to storage in the anaerobic chamber, a 0.2 mM amount of the
reductant, DTT, dissolved in 2 ml of anaerobic water and added to the solution.
After sufficient growth was present in the TYG culture bottles, the cell culture
was poured into two 250ml Nalgene bottles. The cells were pelleted by spinning at
] 0.000 rpm for 15 min at 4°C with a JA-20 Beckman rotor. The pellet was resuspended
in MOPS buffer (lOml MOPS/250 ml culture pellet). The suspension was transferred to a
50ml centrifuge tube and capped.
The cells were pelleted by spinning at 10,000 rpm for 15 min at 4°C. The pellet
was again resuspended in MOPS buffer (lOml/250ml culture). Note: The volume can be
adjusted based on the pellet size. The supernatant was removed and lOml MOPS buffer
was added. A 10 III amount of mutanolysin was added and the pellet plus buffer solution
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was incubated at 37°C for 2h. Next, the samples were placed on ice to cool for
approximately 2 min. The samples were sonicated, using a flat tip sonicator probe. The
sonicator was set at 2 sec pulses, 60% output control and pulsed 15-25X with a flat tip.
To avoid excessive foaming and heat, the sample was mixed gently and placed on ice for
I min following each round of pulsing. Sonication was repeated 2 to 4 more times. The
sonicated sample was then poured into an ultracentrifuge tube. The sample was spun at
31,000 rpm at 4°C for 35 min in a Ti50.2 Beckman rotor. The pellet was resuspended in
10ml MOPS (250ml culture) and transferred into a plastic ultracentrifuge tube. The
pellet was broken up by homogenization. A 0.05g amount (0.5% final cone.) of CHAPS
was added directly to each 10mI sample and stirred at 4°C overnight. The following day,
the sample was spun at 31,000 rpm for 35 min at 4°C. The supernatant was collected to
perform a reduced CO Spectrum on each sample. The supernatants were stored at -80°C.
Determination of Protein Concentrations of Supernatants using the Folin Reaction.
Reagent A cuntained 2g of Na2C03 in 100 mt of O. IN NaOH. Reagent B contained
0.05g of CuS04-5H20 in 10 ml of 1% (W/V) solution of Sodium Tartrate. Reagent C
consisted of a combination of 50ml of Reagent A mixed with Iml of Reagent B. Reagent
o was comprised of 1 N Folin-Phenol. A 100 j.ll amount of the protein sample was added
to 300 j.ll of water. Next, 2ml of Reagent C was added and the solution was vortexed.
The sample was left to stand for 10 min. A 200 j.ll amount of Reagent 0 was added,
vortexed and left to stand for 30 min. The samples were read at 750 nm with a Shimadzu
UV-160IPC (Columbia, MD). In this experiment, bovine serum albumin (BSA) was
used as the control.
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Protein Preparation for 8DS-PAGE.
The calculations were paired up with the correct corresponding protein sample. If the
sample was concentrated (> 150 I-1g), a buffer consisting of deionized water was added to
make the final volume equal 150J,.lg/j..d. If the sample was too dilute « 150llg), it was
split into 150 III aliquots and two or more simultaneous preparations were carried out.
Each 150 1-11 sample was placed into a 1.5 ml microcentrifuge tube and the following was
added: 600 J.ll methanol, 150 1-11 chloroform, and 450 J.ll water. The sample was vortexed
for I minute then spun at 14,000 rpm for 2 minutes. The upper layer was discarded,
leaving only the interface and lower layer. If samples were originally too dilute, the
multiple aliquots were combined into one sample tube. To the interface and lower layer,
300 J.ll of methanol was added and the tube was inverted four times to help clear the sides
of the microcentrifuge tubes of any protein debris. The sample was spun at 14000 rpm
for 3 mins. The supernatant was removed and the pellet was dried in a speed vacuum
with a low heat setting for 10 mins to remove the residual methanol. To the dry pellet, 20
J.ll of water and 5 J.ll of tracking dye was added. The sample was vortexed briefly, boiled
for 5 min, vortexed again then spun for 1 minute to pellet insoluble debris. The sample
was then ready for electrophoresis.
8DS-PAGE procedure.
The running and stacking gels were prepared (40% acrylamide, 0.5 and 1.5 mM Tris
buffer, water, 10% SDS, 10% APS, and TEMED) and loaded with the protein samples,
along with a BIORAD SDS-PAGE molecular weight standard, broad range. The samples
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were run at 200 V for 45 min. Following electrophoresis, the gels were placed into a
Coomassie Blue Staining solution for 24 hrs. The following day, the gels were destained
with a 50/50 water-methanol solution. The final product was vacuum dried for data
evaluation and analysis.
Silver Stain Procedure.
The gels were silver stained using the manufactured BIORAD Silver Stain Plus Kit(16).
This procedure included four main steps: Fixative Step, Rinse Step, Staining and
Developing Step, and the Stop Step. The reagents were provided and steps were
followed exactly to the corresponding manual(16). The SDS-PAGE gels, stained with
coomassie blue. were destained prior to the start of the silver staining procedure.
Rotofor Cell Procedure.
The BlORAD Rotofor cell is an isoelectric focusing apparatus used for protein separation
and purification. This apparatus incorporates a cylindrical focusing chamber with an
internal ceramic cooling finger. Anion and Cation Exchange solutions were degassed for
10 min prior to the assembly of apparatus. The apparatus was equilibrated using a
sample run containing deionized water. The BIORAD Rotofor Cell Instruction Manual
was followed completely for the loading, running, and harvesting of the protein samples.
The 150 /-lg protein sample, which contained ampholytes and urea were loaded into the
apparatus, using a large syringe. Any air bubbles that collected while loading the
chamber, were removed prior to the running of the procedure. The power supply was set
at 12 W for approximately 4 hours. The samples were harvested by a vacuum source into
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fraction tubes. The pH was tested and recorded for each sample prior to labeling and
storage.
Results.
Based on the following procedures, SDS-PAGE gels, CO Spectrums, and Silver Stains,
the following results for each strain are provided. For each strain, the four supernatants
were examined. The four supernatants are: N1 (non-treated, supernatant 1), I I
(phenobarbital-induced, supernatant 1), N2 (non-treated, supernatant 2), and 12
(phenobarbital-induced, supernatant 2). Supernatant 1 represents the cytoplasmic
proteins whereas supernatant 2 consists of the membrane-bound proteins.
Bifidobacterium adolescentis. The protein concentrations were 141 ~g for N 1, 144 ~g
for II, 315 ~g for N2, and 223 ~g for 12. B. adolescentis showed no protein induction
based on the 10% SDS-PAGE gel, stained with Coomassie blue (Fig. 1). There were also
no inductions present on the Silver Stain gel (data not shown). No peaks, indicative of the
presence of a cytochrome, were found with the CO Spectrum assay (data not shown).
Bifidobacterium bifidum. A protein induction was observed in the anduced, supernatant 2
lane(I2), at 43 kDa. On the Silver Stain gel, two proteins were identified at 45 and 65
kDa (data not shown). For supernatants II, N2, and 12, a peak around 416-420 nrn was
seen. However, the absorbancy values were low at -0.028, 0.005, and -0.046
respectively (data not shown). Previous findings by other researchers, showed an
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induction in supernatant II at 40 and 48 kDa. For supernatant 12, previous gels show an
induction at ~33 kDa (data not shown).
Bifidobacterium breve. No protein inductions were seen for B. breve on the Silver Stain
(data not shown) or SDS-PAGE gels (Fig. 3 &4). For supernatant 12, a peak at 417 run
was identified with an absorbance of 0.020 (data not shown). Previous SOS-PAGE gels
showed an induction in supernatant II at 40 kDa and in 12 at 38 kDa.
Bifidobacterium infantis. For B. infantis, an induction was seen at approximately 180
kDa for supernatant 12 (Fig. 3). There was no detection of an induction in any of the
Silver Stain gels (data not shown). A CO Spectrum peak was observed at approximately
416 nm for supernatant Nl with an absorbancy of 0.02. For supernatant N2, a peak was
observed at 430 nm with an absorbance of 0.05 (data not shown). Previous work showed
SDS-PAGE gel protein inductions in supernatant Il at 35 kDa. This sample was
evaluated further, using better separation techniques, such as the Rotofor, followed by a
Silver Stain. However, after isoelectric focussing with the Rotofor, evidence of the
previous induction at 35 kDa was absent. The silver stain gel confirmed that the
suspected induced protein was unable to be isolated and identified. This could be due to
the sample being lost during loading or harvesting of the Rotofor chamber.
Bifidobacterium longum. No inductions were observed for 50S-PAGE (Fig. 4) and
Silver Stain gels, or CO Spectrum profiles (data not shown). It should be noted that on
the SDS-PAGE gels, supernatants NI and Il, the tracking dye was too dilute to detect
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any reliable results. Therefore, the SDS-PAGE gel was repeated, still consistent with
previous negative results.
Conclusions.
Of the five Bifidobacterium spp. that were tested, no significant protein inductions were
observed. A significant finding of a protein induction is one that shows up consistently in
the SDS-PAGE and Silver Stain gels for the same supernatant and molecular weight.
This would eliminate the questionability as to whether the protein induction was present
or not. Also, a true induction should be absent in the untreated supernatants. These
findings indicate that there are no significant inductions in any of the five strains tested.
Of the protein inductions that were seen, none have shown to be repeatable or present in
both gel procedures. A CO spectrum peak around 4] 6 to 425 nrn is indicative of a
cytochrome presence. However, the absorbance value must be significant in order to
suggest an induction by a cytochrome P-450. Of the CO spectrum peaks observed in the
4] 6-425 nm range, none have shown an indication of the presence of a cytochrome P-450
protein. Of the Bifidobacterium spp. that were tested, our results show that phenobarbital
had no significant effect on the induction of a cytochrome P450 protein. Evidence of a
cytochrome P450 complex in our samples was not detected. Because of the lack of
evidence for a cytochrome P450 present in our samples, we considered the alternative
hypothesis that another complex, or reaction is responsible for the degradation of
phenobarbital. This could be another unidentified system analogous to the inducible lac
operon system that allows the metabolism oflactose in E. coli(4).
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Figure 1. SDS-PAGE gel of B. ado/escentis
M NI II N2 12
200 -.
66-...
21~
t0% SDS-PAGE gel of B. adolescentis protein fractions. M is molecular weight marker
(in kDa.), Nt is non-treated, fraction 1, II is phenobarbital-treated, fraction 1, N2 is non-
treated, fraction 2 and 12 is phenobarbital-treated, fraction 2.
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Figure 2. SDS-PAGE gel of B. bifidum
M NI II N2 12
21-~a
10% SDS-PAGE gel of B. bifidum protein fractions. M is the molecular weight marker
(in kDa.), Nl is non-treated, fraction 1,11 is phenobarbital-treated, fraction 1, N2 is non-
treated, fraction 2, and 12 is phenobarbital-treated, fraction 2. A protein induction is
indicated by a c::::J
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Figure 3. SDS-PAGE gel of B. breve and B. infantis
M
200 ------. - .-
116 I~,
66 ----+
45 ------.
21--~"""
~. :
2 3 4 5 6 7
-
8
M is the molecular weight marker (in kDa), Lanes I through 4 are B. breve and Lanes 5
through 8 are B. infantis. Lanes 1 and 5 are non-treated, fraction 1, lanes 2 and 6 are
phenobarbital-treated, fraction 1, lanes 3 and 7 are non-treated, fraction 2, and lanes 4 and
8 are phenobarbital-treated, fraction 2. A protein induction is indicated by a c:::=J
20
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Figure 4. SDS-PAGE gel of B. breve and B. longum
M 123456 7 8
200 -.
66 -.
21-.
• J
M is the molecular weight marker (in kDa.). Lanes I through 4 are B. breve and lanes 5
through 8 are B. longum. Lanes I and 5 are non-treated. fraction I, lanes 2 and 6 are
phenobarbital-treated, fraction 1, lanes 3 and 7 are non-treated, fraction 2, and lanes 4 and
8 are phenobarbital-treated fraction 2.
21
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-CHAPTER 3
THE METABOLISM OF PHENOBARBITAL, A DRUG USED FOR EPILEPSY,
BY INTESTINAL FLORA, BIFIDOBACTERJUMADOLESCENTIS AND
BIFIDOBACTERIUM BIFJDUM.
Introduction. Human intestinal flora play a large role in metabolizing a variety of
compounds that travel through the digestive tract(22). This contributes to their extremely
diverse metabolic capacity, which unfortunately, is not fully understood. To better
understand their metabolic capacity, our investigation has focused on two major intestinal
microfloral strains, Bijidohacterium adolescentis and Blfidobacterium bijidum(39). Our
hypothesis is based on previous reports that Bifidobacterium may possess a P450-likc
protein that may participate in the metabolism of various xenobiotics. The results from
this study have detennined the ability of these microbes, under anaerobic conditions, to
metabolize Phenobarbital, a phannaceutical drug used to treat epilepsy and a potent
inducer of hepatic cytochrome P-450. The effects of a range of phenobarbital
concentrations on bacterial growth were quantitated and the generated metabolite
(benzeneacetamide) was analyzed by the Ge/MS method. The results of this study
demonstrated that phenobarbital inhibited the growth of the slower growing B. bijidum
compared to the faster growing B. adolescentis. Both strains were able to metabolize
phenobarbital to benzeneacetamide, but the faster growing B. adolescentis exhibited
greater metabolizing activity. The results of this study demonstrate that intestinal flora
can metabolize pharmaceuticals, which has significant clinical implications.
The metabolic capacity of intestinal microorganisms is vast and not well
understood (14, 28). The intestine contains a massive, as well as, a variety of bacterial
genera, which participate in the metabolism of different xenobiotics. Bifidobacterium
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species are considered a major constituent in the small and large intestine. They are
gram-positive bacteria, irregular rod shape, and strict anaerobes, which allow for their
predominance as normal gut flora near the villi of the colon (33). In addition, they are
known to have a positive effect on the host, as they help maintain the intestinal microbial
balance, as well as discourage other pathogens from colonizing.
Each day, our bodies take up significant amounts of material that are not used as
energy substrates or as building blocks for biological matrices. Xenobiotics are
compounds that fall into this category. If these xenobiotics accumulated in an organism,
the resulting accumulation could affect the physiological systems. Elimination of these
products occurs by a process called biotransformation, in which phase I and phase II
enzymes are involved. The major elimination pathway of these products involves
excretion via bile, expired air, feces and urine.
The metabolism of phenobarbital occurs in the liver as a result of the CYP 2C
cytochrome P450( 17,25). The product generated is either the para-hydroxyphenobarbital
(43) and/or phenobarbital N-glucoside (l). The extent to which phenobarbital is
converted to this compound and its conjugates is not known (43). The purpose of this
study is to determine if major intestinal strains, such as Bifidobacterium, are involved in
the metabolism of phenobarbital.
The significance of this study is that Bifidobacterium is a major intestinal strain
commonly found in many individuals and its ability to metabolize xenobiotics, such as
phenobarbital, may have a profound effect on the physiology of the host. Secondly, as
probiotic therapy is becoming more popular, it is important that we understand the
different metabolic systems that are found in wild strains (ATCC Bifidobacterium) and
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probiotic strains (Bifidobacterium sp). Lastly, characterizing Bifidobacterium's
metabolic capacity in terms of whether enzymes systems such as cytochrome P450 exist
is important as they may participate in the metabolism and generation of detoxified or
toxified products, which can have a positive or negative affect on human health.
Materials and Methods.
Bacterial strains.
Bifidobacterium adolescentis ATCC 15703, Bifidobacterium bifidum ATCC 15696
Culture media and growth curves.
The reference strains were cultured in anaerobic Chopped Meat media for 48 hours. The
cultures were then aseptically transferred to anaerobic TYG media and incubated for 24
hours at 37°C. Following incubation, 100 JlI of cells were subcultured to 5 ml TYG
anaerobic tubes containing different concentrations of phenobarbital (final concentrations
omM, 5 mM, 10 mM, and 20 mM). A gram stain was performed on each sample to
ensure purity of the culture. A uniform group of gram-positive cells was considered an
axenic culture. The experiments were performed in triplicate for all strains tested. The
growth was determined by measuring the optical density (G.D.) at 600 nm using a Spec-
20 (Spectronic 20-D). The Spec-20 was calibrated to zero absorbance by using blank
media tubes with the appropriate concentration of phenobarbital (0 mM, 5 mM, 10 mM,
and 20 mM). Time points were recorded between 0 to 100 hours. Following the growth
curve, the samples were stored at -80°C. The a.D. data was compiJed and graphed using
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Microsoft Excel Chart Wizard. The protein profiles for each sample were analyzed by
SDS-PAGE using a methanol-chlorofonn extraction procedure(21 ).
Gas Chromatography/ Mass Spectrometry.
The -80°C stored samples were also analyzed using GC/MS (Gas Chromatography/Mass
Spectroscopy) (27). To a borosilicate culture tube containing 500 ).11 of sample, a 125).11
amount of 1M K2HP04 was added, followed by 3.25 ml of ether/chloroform (2:1)
solution. This solution was vortexed for one minute and then centrifuged at 1200 rpm for
2 minutes. The organic phase (top layer) was retained and subjected to N2 gas until
dryness occurred. The sample was then reconstituted with 100 ).11 of ethyl acetate and
appropriate dilutions were made. The samples were then injected into the GC/MS
(HP5890, HP5989B) using a OB5, 30 meter column at 0.25 microns. The data was
analyzed by using a digital integrator.
Results
Growth curves analysis.
Table 2 shows the doubling times for Bifidobacterium adolescentis (Fig. 5) and
Bifidobacterium bifidum (Fig. 6) under different concentrations of phenobarbital. There
was an overall increase in doubling time as the concentration of phenobarbital was
increased. There was also an extended lag time for the 20 mM concentration of
phenobarbital, while the lesser concentrations displayed a lag phase that resembled the
control. The slope of the log phase for both B. adolescentis and B. bifidum were
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calculated to determine if there was any change in the rate of growth for the various
concentrations of phenobarbital (Fig. 7). The protein profiles for all samples showed no
major induction of proteins (data not shown).
Gas Chromatography and Mass Spectrophotometry (GCIMS).
The -80°C samples were thawed and prepared for the GCIMS analysis. The GC data for
both strains showed two major peaks at thirteen and eighteen and half minutes for all
concentrations tested (Fig. 10,11,12,14,15,16). The OmM Phenobarbital blank (Fig. 8 &
13), 5 mM phenobarbital degradation control (Fig. 9) and sterile media showed no m~ior
peaks. The MS identified the two major peaks as phenobarbital and benzeneacetamide.
The phenobarbital has undergone reductive cleavage as the terminal nitrogen obtained a
hydrogen atom. It appears the phenobarbital was cleaved at three positions, releasing the
CH3CH2, and CONCa molecules (Fig. r9). The percent of product generated in relation
to the parent compound was detennined hy measuring the area under the peaks and its
presence over a period of time (Table 3). The absence of the benzeneacteamide peak in
our control samples suggests the metabolism of phenobarbital is due to Bifidobacterium.
For B. adolescentis (Fig. 18), ahout 40% of the phenobarbital was metabolized to
benzeneacetamide in the 5 mM sample, 30% in the 10 mM sample, and 45% in the 20
mM sample. For B. bifidum about 10% of the phenobarbital was metabolized to
benzeneacetamide in the 5 mM sample, 40% in the 10 mM sample, and 10% in the 20
mM sample. The ratio of metabolite, benzeneacetamide, to parent compound,
phenobarbital, was also calculated to detennine if metabolism of phenobarbital was fixed
or variable dependent upon the concentration (Fig. 17). We found for B. adolescentis
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that as the concentration of phenobarbital was increased, so did the yield of metabolite.
However, for B. bifidum, the abundance of metabolite increased as concentration
increased, except for 20 mM, in which the amount of metabolite was decreased.
Discussion.
Intestinal flora possess a diverse metabolic system due to their constant exposure to
different xenobiotics(33, 34). Their metabolic products are either eliminated by way of
feces or they are absorbed into the gastrointestinal mucosa and eventually make their way
into the liver. The effects that intestinal flora have on the ex.pression of liver enzymes
such as cytochrome P450 has been documented(l7). Altering the expression of
cytochrome P450 can affect the detoxification and metabolite activation processes, which
can impact human health. Therefore, our understanding of how specific intestinal
microbes metabolize xenobiotics is important.
The objective of our study was to determine if phenobarbital, a potent inducer of
cytochrome P450 and a drug used to treat epilepsy, was metabolized by Bifidobacterium,
which is a major intestinal flora. Our results demonstrated an etfect on the growth rate
shown by an increase in the lag phase with increasing concentrations of phenobarbital.
An extended lag phase was observed only for the most concentrated sample (20 mM),
while the other samples (5mM, 10 mM) were slightly higher then the 0 roM sample. The
growth rates of B. bifidum (22.38/hr) were significantly slower than B. adolescentis
(7.17/hr). As a result, the percentage of product generated for the slower growing B.
bifidum was overall less when compared to the faster growing B. adolescentis. In
addition, phenobarbital seemed to affect the growth of the slower growing B. bifidum
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more than the faster growing B. ado/escentis. These results suggest the faster growing
and more resistant B. ado/escentis was able to metabolize phenobarbital more extensively
than the slower growing and more sensitive B. bifidum. Overall, phenobarbital was
metabolized by both strains.
The experimental concentrations of phenobarbital used in this study have a
clinical significance. A 5 mM final concentration is comparable to the upper level dose
of an average adult. Alternatively, the 20 mM concentration is analogous to that of a
lethal dose to the average human. Therefore, the possibility of Bifidobacterium in the
human intestinal tract metabolizing phenobarbital is likely. Also under in vivo
conditions, the fate of benzeneacetamide is unknown. Because it contains a toxic
benzene ring, the absorption and metabolism by liver gastrointestinal and/or liver
enzymes is possible thereby releasing the toxic benzene molecule into the surrounding
environment.
The unique finding of the study showed for the first time how Bifidobacterium, a
major intestinal microflora, was capable of metabolizing phenobarbital into
benzeneacetamidc which is dramatically different then what occurs in mammals (Fig. 19)
as phenobarbital is normally metabolized by the hepatic cytochrome P450 into p-
hydroxy-phenobarbital and/or phenobarbital N-glucoside (1).
Overall, our results have clinical significance regarding the role of intestinal flora
in the metabolism of foreign compounds, such as phenobarbital. Our results demonstrate
that two strains, Bifidobacterium adolescentis and B. bifidum, metabolize phenobarbital
to a potentially toxic substance, benzeneacetamide. Therefore, future studies should
include more pharmaceutical testing involving intestinal flora, prior to drug approval.
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Since Bifidobacterium spp. is a major component of the intestinal flora population that is
able to metabolize phenobarbital to the compound, benzeneacetamide other clinical
significance needs to be evaluated. There 1S no literature stating whether
benzeneacetamide is an active metabolite of phenobarbital, indicating that the
metabolism of phenobarbital could be dangerous to a patient that relies on the ability of
phenobarbital to control seizures. Also, we have shown that an intestinal bacterium can
metabolize the phenobarbitaL Therefore, it leaves us to ask the question, what other
compounds can be metabolized by intestinal flora?
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Table 2
Growth characteristics
Doubling time
PB
(mM)
o
5
10
20
B. adolescentis
7.17
9.08
11.36
13.28
B. bifidum
22.38
21.55
47.10
71.90
These values represent the period of time in which the microorganisms, B. adolescentis and B. bifidum,
have a two-fold increase in the absorbance value. The change in time was measured by the end10g phue minus
beginninglog phase'
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Table 3
Percentage of product generated
PB
(mM)
o
5
10
20
Percent
B. adoJescentis
o
40
30
45
B. bifidum
o
10
40
10
This table shows the percent of product. benzeneacetamide, that was produced when compared to
the parent compound, phenobarbital.
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Figure 5. Growth Curve of B. adolescentis in the Presence of Phenobarbital
B. adolescentis in the Presence of Phenobarbital
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The y axis represents the absorbance at 600 nm and the x axis represents time, in hours. Four
concentrations of phenobarbital were tested: 0 roM, 5 roM, 10 mM and 20 mM.
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Figure 6. Growth Curve of B. bifidum in the Presence of Phenobarbital
B. bifidum in the Presence of Phenobarbital
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The y axis indicates absorbance at 600 nm, and the x axis is time, in hours. Four concentrations of
phenobarbital were tested: 0 mM, 5 mM, 10 mM and 20 mM.
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Figure 7. Slope of the Log Phase versus Various Concentrations of Phenobarbital
Slope of the Log Phase vs. Concentration of Phenobarbital
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The slope of the log phase was calculated by taking the difference in the y axis divided by the x
axis for only the log phase. For example, the absorbance at the start of the log phase was
subtracted from the absorbance at the end of the log phase. This difference was divided by the
change in time over the two points. The diamond shape represents B. ado/escentis and the square
is B. bifidum.
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Figure 8. GelMS Results for B. adolescentis 0 mM Phenobarbital
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No peaks from parent compound (phenobarbital) or metabolite (benzeneacetamide) were
detected.
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Figure 9. Ge/MS Results for B. adolescentis 5 mM Phenobarbital Degradation Control
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Figure 10. Ge/MS Results for B, adolescentis 5 mM Phenobarbital
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Figure 11. GC/MS Results for B. adolescentis 10 m.M Phenobarbital
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Figure 12. GelMS Results for B. adolescentis 20 mM Phenobarbital
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Figure 13. GelMS Results for B. bifidum 0 roM Phenobarbital
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No peaks from parent compound (phenobarbital) or metabolite (benzeneacetamide) were
detected.
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Figure 14. GCIMS Results for B. bifidum 5 mM Phenobarbital
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Figure 15. Ge/MS Results for B. bifidum 10 mM Phenobarbital
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Figure 16. GelMS Results for B. bifidum 20 mM Phenobarbital
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Figure 17. Ratio of Benzeneacetamide to Phenobarbital versus Concentration
Benzeneacetamlde I Phenobarbital vs. Concentration of Phenobarbital
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Figure 18. Metabolism of Phenobarbital from B. adolescentis
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CHAPTER 4
CONCLUSIONS AND DISCUSSION
This work began with the hypothesis that intestinal flora may contain a
cytochrome P-450-like protein, in which to utilize for the metabolism of xenobiotics,
similar to its eukaryotic partner located primarily in the liver. Phenobarbital was selected
for experimentation because it is a compound that has been routinely used in the
laboratory for the induction of cytochrome P450 complexes. Previous research has
shown that phenobarbital is a strong inducer of specific cytochrome P-450 complexes in
mammals. Following experimentation, it was determined that the chosen intestinal
microorganism, Bifidobacterium, did not contain such an enzyme system. This was
demonstrated by the lack of a 45 to 50 kDa protein induction in the SDS-PAGE and
Silver Stain gels. Next, the absence of the cytochrome P450 characteristic peak at 450
run made it evident that a P450 complex was not present in Bifidobacterium.
These findings led to several questions, including why this was occurring and
what effect does the pharmaceutical, phenobarbital, have on the survival of the
microorganism? It was the need to uncover the answer to these questions that led the
researcher to proceed with the following experiments.
The second part of this project consisted of investigating what affect
phenobarbital had on the growth of the microorganism, Bifidobacterium. Growth curve
experiments were performed. The results of this experiment demonstrated an increase in
doubling time as the concentration of phenobarbital was increased. Next, the growth
curve samples underwent GC/MS evaluation to determine if phenobarbital was being
metabolized in the presence of the microorganism, Bifidobacterium. The MS identified
47
two peaks as phenobarbital and benzeneacetamide. In contrast, the OmM phenobarbital
blank, 5 mM phenobarbital degradation control (no bacteria) and sterile media showed no
major peaks. In the presence of Bifidobacterium, phenobarbital had undergone reductive
cleavage as the terminal nitrogen obtained a hydrogen atom. It appeared that the
phenobarbital was cleaved at three positions, releasing the CH3CH2 and CONCa
molecules. The unique finding of this study showed for the first time how
Bifidobacterium, a major intestinal microorganism, was capable of metabolizing
phenobarbital into benzeneacetamide.
One explanation as to why phenobarbital metabolized by Bifidobacterium can
best be described by the lac operon system in E. coli to utilize lactose as a carbon source.
The lactose (lac) system is still the best-studied example of gene regulation. The
mechanism of regulation of gene expression is today one of the most actively studied
problems in molecular biology, in good part as a result of the pioneering work of Jacob
and Monod on the control of genes involved in lactose metabolism in the bacterium, E.
coli (3, 4, 29). In E. coli, two proteins are necessary for the metaholism of lactose: the
enzyme B-galactosidase. which cleaves the disaccharide lactose (a B-galactoside) into the
monosaccharides galactose and glucose, and lactose permease, a protein required for
transport of lactose across the cell membrane into a cel1(26). The regulatory mechanism
of the lac system has many features. First, the lactose-utilization system consists of two
kinds of components; structural genes needed for transport and metabolism of lactose and
regulatory elements, such as the lad gene, lacO operator, and the lac promotor. The lac
operon system is inducible and lactose is the inducer(4, 20, 26). It is possible that the
delay in lag phase we have seen in our growth curve experiments is due to the presence
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of an inducer, in our case, phenobarbital, that activates a 'hypothetical' phenobarbital
operon. This phenobarbital operon may be responsible for the production of biological
elements, such as drug metabolizing proteins that have the ability to utilize phenobarbital
Our results have clinical significance regarding the role of intestinal flora in the
metabolism of foreign compounds, such as phenobarbital. Our results have demonstrated
that Bifidobacterium can metabolize phenobarbital to a potentially toxic substance,
benzeneacetarnide. Because intestinal flora possess a diverse metabolic system, future
studies should include more pharmaceutical testing prior to drug approval.
Future work in this area would be to see if the same metabolic phenomenon exists
in other intestinal microorganisms. The intestinal tract, and the microorganisms that
colonize it. is an area that has yet to be examined thorougWy. The comprehension of the
degradation of xenobiotics by intestinal microorganisms is generally overlooked yet may
provide insight to the understanding of human health and well-being.
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